SslE elicits functional antibodies that impair in vitro mucinase activity and in vivo colonization by both intestinal and extraintestinal Escherichia coli strains

Author
Nesta, Barbara, Valeri, Maria, Spagnuolo, Angela, Rosini, Roberto, Mora, Mmarirosa, Donato, Paolo, Alteri, Christopher J., Del Vecchio, Mariangela, Buccato, Scilla, Pezzicoli, Alfredo, Bertoldi, Isabella, Buzzigoli, Lapo, Tuscano, Giovanna, Falduto, Maria, Rippa, Valentina, Ashhab, Yaqoub, Bensi, Giuliano, Fontana, Maria Rita, Seib, Kate, Mobley, Harry L. T., Pizza, Mariagrazia, Soriani, Marco, Serino, Laura

Published
2014

Journal Title
PLoS Pathogens

DOI
https://doi.org/10.1371/journal.ppat.1004124

Copyright Statement
Copyright 2014 Nesta et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License CCAL. (http://www.plos.org/journals/license.html)

Downloaded from
http://hdl.handle.net/10072/62552
SslE Elicits Functional Antibodies That Impair In Vitro Mucinase Activity and In Vivo Colonization by Both Intestinal and Extraintestinal Escherichia coli Strains

Barbara Nesta1, Maria Valeri1, Angela Spagnuolo1, Roberto Rosini1, Marirosa Mora1, Paolo Donato1, Christopher J. Alteri2, Mariangela Del Vecchio1, Scilla Buccato1, Alfredo Pezzicoli1, Isabella Bertoldi1, Lapo Buzzigoli1, Giovanna Tuscano1, Maria Falduto1, Valentina Rippa1, Yaqoub Ashhab3, Giuliano Bensi1, Maria Rita Fontana1, Kate L. Seib4, Harry L. T. Moley2, Mariagrazia Pizza1, Marco Soriani1*, Laura Serino1

1 Novartis Vaccines and Diagnostics Srl, Siena, Italy, 2 Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, United States of America, 3 Biotechnology Research Center, Palestine Polytechnic University, Hebron, Palestine, 4 Institute for Glycomics, Griffith University, Gold Coast Campus, Queensland, Australia

Abstract

SslE, the Secreted and surface-associated lipoprotein from Escherichia coli, has recently been associated to the M60-like extracellular zinc-metalloprotease sub-family which is implicated in glycan recognition and processing. SslE can be divided into two main variants and we recently proposed it as a potential vaccine candidate. By applying a number of in vitro bioassays and comparing wild type, knockout mutant and complemented strains, we have now demonstrated that SslE specifically contributes to degradation of mucin substrates, typically present in the intestine and bladder. Mutation of the zinc metallopeptidase motif of SslE dramatically impaired E. coli mucinase activity, confirming the specificity of the phenotype observed. Moreover, antibodies raised against variant I SslE, cloned from strain IHE3034 (SslEIHE3034), are able to inhibit translocation of E. coli strains expressing different variants through a mucin-based matrix, suggesting that SslE induces cross-reactive functional antibodies that affect the metallopeptidase activity. To test this hypothesis, we used well-established animal models and demonstrated that immunization with SslEIHE3034 significantly reduced gut, kidney and spleen colonization by strains producing variant II SslE and belonging to different pathotypes. Taken together, these data strongly support the importance of SslE in E. coli colonization of mucosal surfaces and reinforce the use of this antigen as a component of a broadly protective vaccine against pathogenic E. coli species.


Editor: Vanessa Sperandio, University of Texas Southwestern Medical Center, United States of America

Received September 19, 2013; Accepted March 31, 2014; Published May 8, 2014

Copyright: © 2014 Nesta et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was mainly supported by internal funding from Novartis Vaccines and Diagnostics. However, it was also partly supported by funding under both the grant PON01_00117 from the Italian “Ministero dell’Istruzione, dell’Università e della Ricerca” and the EMIDA ERA-NET “Coordination of European Research on Emerging and Major Infectious Diseases of Livestock” (financed by the European Commission’s Seventh Framework Programme, project no. 219235) as part of the project “Combating colibacillosis—a genomics-based approach.” This work was supported in part by Public Health Service grant NIH. R01 AI43363 from the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: SN, MV, AS, RR, MM, PD, MDV, SB, AP, IB, LB, GT, MF, VR, GB, MRP, MP, LS and MS are employed by Novartis Vaccines s.r.l. (Siena, Italy). This does not alter our adherence to all PLOS Pathogens policies on sharing data and materials.

* E-mail: marco.soriani@novartis.com

Introduction

Pathogenic E. coli can be broadly classified as either extraintestinal pathogenic E. coli (ExPEC), the main cause of urinary tract infection (UTI), newborn meningitis and sepsis, or as intestinal pathogenic E. coli (InPEC) causing diarrhoeagenic infections. Among the intestinal pathogens there are at least six well-described groups: enteropathogenic E. coli (EPEC), enterohemorrhagic E. coli (EHEC), enterotoxigenic E. coli (ETEC), enteraggregative E. coli (EAEC), enteroinvasive E. coli (EIEC) and diffusely adherent E. coli (DAEC) [1]. The plasticity of the E. coli genomes, due to the ability to gain or lose virulence attributes by horizontal gene transfer, allows these organisms to colonize different sites. Indeed, E. coli possesses an array of virulence factors which include various adhesins, capsule, iron-transporters, toxins and proteases (reviewed in [1]). However, recent studies have suggested that the pathogenesis of E. coli is considerably more complex than previously appreciated involving additional virulence factors [2,3]. The absence of a broadly protective vaccine against pathogenic E. coli is a major problem for modern society since diseases caused by these bacteria are associated with significant human suffering and high healthcare costs. The overall problem is exacerbated by the rising rates of multi-drug resistant strains and by the emergence of new sequence types and hypervirulent strains [4-9]. We have recently proposed ECK1_33815 as a promising vaccine candidate able to confer protection in a murine model of sepsis [10,11]. This protein, described as SdE [for secreted and surface-associated lipoprotein from E. coli] and formerly known as YghJ [12,13], appears to be required for biofilm formation and for virulence of EPEC strains [14], although more recent evidence indicates that SdE has no effect on adherence and biofilm formation in atypical EPEC strains [15]. Thus, the function of
SslE is a mucus-secreting extracellular protein from *Escherichia coli* that plays a role in facilitating bacterial adhesion and entry of the virus into epithelial cells [20]. The SslE protein is involved in the mucin degradation by *E. coli*, allowing the bacteria to penetrate the sterile inner mucus layer leading to interaction with host cells. SslE is involved in *E. coli* surface localization at distinct foci and is secreted through a type II secretion system (T2SS), an exporting apparatus typically used by Gram-negative bacteria to secrete virulence determinants [16]. Two T2SSs exist in *E. coli*, designated as alpha (T2SSα) and beta (T2SSβ) [17]. The T2SSβ operon is composed of three genes, *yghJ*, *yghG*, and *yghF* upstream of *gspC*. The first gene, *yghJ*, encodes for SslE protein. A functional T2SSβ secreting a cognate SslE protein was recently studied in the non-pathogenic *E. coli* W strain [18]. Recently, it was reported that SslE belongs to a new sub-family of extracellular zinc-metalloproteases, characterized by a M60-like domain representative of a new extracellular zinc-metalloprotease sub-family. In particular, *in vitro* analysis of the ability of an *sslE* knockout mutant strain to transverse an agar-based mucin matrix revealed that SslE is essential to *E. coli* mucusase activity. Evidence showing that SslE induces functional antibodies, preventing both *in vitro* mucin degradation but also *in vivo* gut, kidney and spleen colonization, further support the hypothesis that SslE may facilitate *E. coli* colonization by favoring the penetration of the sterile inner mucus layer leading to interaction with host cells. Finally, the ability of SslE to induce protective immunity against sepsis, linked to its presence among different pathotypes, supports the use of such an antigen as a broadly protective *E. coli* vaccine candidate.

**Results**

**SslE localizes on *E. coli* surface at distinct foci**

It has been recently reported that although SslE is secreted by a T2SS, it is also found on the bacterial cell surface [10,14]. Confocal analysis of Z-stack images of an ExPEC strain IHE3034 stained for SslE and deconvoluted using Volocity Software, revealed that the antigen is translocated on the bacterial surface at specific foci (Fig. 1A). Of interest, we observed that only a small proportion of bacteria (3% of total number) expressed the antigen on the surface (Fig. 1A). We determined that this phenotype is attributable to the polysialic acid capsule (K1 antigen) that it responsible for masking SslE on the bacterial surface (Fig. S1). The *sslE* deletion mutant strain (IHE3034 ΔsslE) did not show any surface labeling (Fig. 1B), confirming the specificity of the signal. Complementation of the mutant strain with a pET24b+ plasmid carrying the *sslE* gene (including the promoter region) restored antigen surface localization (Fig. 1C). To exclude the possibility that the SslE signal at the bacterial surface could be partially attributed to the re-association of the secreted form of the protein to the membrane, we co-cultured the IHE3034 wild-type (WT) strain with the IHE3034ΔsslE strain engineered to express the GFP fluorescent protein. Staining of bacteria using SslE antibodies conjugated to FITC, revealed that the antigen was exclusively detected on the surface of the WT strain and not on the fluorescent bacteria, indicating that no SslE re-association occurred (data not shown).

**SslE is involved in *in vitro* mucin degradation by IHE3034 strain**

As recently reported by Nakjiang and collaborators [19], HEXXHX8.24/E is the full putative metalloprotease core motif of SslE (residues: 1304–1322; SslE accession number: YP_006102500),...
SslE Is a Mucinase Facilitating E. coli Infections

exclusively present in a recently characterized zinc metallopeptidase sub-family possessing mucinase activity [19]. The pattern "HEXXHX(6,24)E" consists of a conserved glutamate residue localized 8 to 24 amino acids from the "HEXXH" motif. To investigate the putative mucinolytic activity of SslE, we have applied a number of in vitro assays previously reported to specifically detect mucinase activity in bacteria [21–24]. The first approach is based on the use of bacteria grown on agar plates containing 0.5% bovine submaxillary mucin followed by amido black-staining [25,26]. Plates containing the IHE3034 WT strain incubated for 24 h revealed clear zones of mucin lysis (Fig. 2A). However, no cleared areas were detected when the IHE3034ΔsslE knockout (KO) strain was added to the plates, indicating the specific contribution of SslE to the mucinase activity. Incubation of mucin-based plates with the complemented strain IHE3034ΔsslE::sslE_WT carrying the WT sslE gene fully restored the wild-type phenotype as assessed by the lack of amido black staining. To investigate the role of the M60-like core motif in mucin lysis, we transformed the IHE3034ΔsslE strain with the pET24b+ plasmid carrying a triple mutation in the putative metallopeptidase motif of SslE, YVGY vs. HEVGH. In particular, we introduced hydrophobic elements in the HEXXH motif (Y and V), which by reducing the charge of the enzymatic task are likely to impair the mucinase activity. Testing of this mutant by the amido black assay revealed a phenotype comparable to the sslE KO strain (Fig. 2A). These data were further confirmed by the In Vivo Imaging System (IVIS-Perkin Elmer) technology which allowed the visualization of bacterial migration through the agar-mucin matrix at different time points, using IHE3034 strains engineered for constitutive expression of a luciferase operon (pLux) [27] (Fig. 2B). Briefly, a mid-log bacterial culture of the bioiluminescent strains was loaded in a well created at the center of a mucin-agar plate and bacterial distribution was detected after 24 h of incubation. IHE3034 (pLux) and IHE3034ΔsslE::sslE_WT strains, but not IHE3034ΔsslE::sslE::sslE_mut, were able to spread beyond the site of the initial inoculum (Fig. 2B), confirming that SslE-dependent mucin degradation enables diffusion of E. coli through the agar.

Antibodies against SslE prevent the ability of IHE3034 to cross a mucin-based matrix in a dose-dependent manner

To test the hypothesis that anti-SsslE antibodies may also inhibit mucinase activity in vitro, we developed an in vitro system to quantify the ability of strain IHE3034 WT to transverse a mucin-based gel matrix. An agar-based matrix gel containing 10% bovine submaxillary gland mucins was reconstituted in a 1 mL syringe and bacterial aliquots (10⁶ CFU) were layered on top of the gel and statically incubated for 3 h at 37°C in a vertical position to allow bacterial translocation. At the end of the incubation period, gel fractions were eluted from the bottom of the syringe, diluted and plated for CFU determination. After confirming the impaired phenotype of the sslE KO strain in traversing the mucin matrix compared to the isogenic WT strain (≈2.5 Log reduction) (Fig. 3A), we tested the ability of polyclonal antibodies generated by subcutaneous immunization of rabbit with the full length recombinant SslE from ExPEC strain IHE3034 (anti-S sslEIHE3034) to reduce bacterial translocation through the mucin agar-gel syringe. Anti-SsslE IgGs and IgAs in the rabbit serum were measured by ELISA (Fig. S2A and B). A significant dose-dependent inhibition of bacterial translocation was observed when the mucin-gel matrix was polymerized together with anti-SsslE antibodies (dose range 1:50 to 1:1350) (Fig. 3B). At a dilution of 1:50 the inhibitory effect of SsslE antibodies was evident in all fractions collected, while higher

Figure 2. SsslE mucinolytic activity. (A) Mucin lysis (clear plates) was assessed by amido black staining. IHE3034 wild-type, IHE3034ΔsslE knockout mutant, IHE3034ΔsslE::sslE_WT (complemented with the sslE wild-type gene), and IHE3034ΔsslE::sslE_mut (complemented with the sslE gene mutated in the putative metallopeptidase motif), were grown on plates containing 0.5% bovine submaxillary mucin (SIGMA) and stained with 0.1% (wt/vol) amido black in 3.5 M acetic acid for 30 min and destained with 1.2 M acetic acid. (B) The four strains were engineered for constitutive luciferase expression (pLux operon) and mucinolytic activity was detected by the In Vivo Imaging System (IVIS) technology. Bacterial migration in the mucin-agar plates is shown, from the point of inoculum (time zero; t0) to growth at 24 hours (24 h).

doi:10.1371/journal.ppat.1004124.g002
Figure 3. Anti-SslE antibodies impair translocation of \textit{E. coli} through a mucin-gel matrix. (A) IHE3034 wild-type, the IHE3034\\textit{sslE} knockout mutant, IHE3034\\textit{sslE::sslE}_{WT} (complemented with the \textit{sslE} gene wild-type) and IHE3034\\textit{sslE::sslE}_{mut} (complemented with \textit{sslE} gene mutated in the putative metallopeptidase motif), were loaded on the top of a mucin-gel matrix column polymerized in a 1 ml syringe. After 3 hours at 37°C, eluted fractions were collected and plated for CFU counting. The results were reported as percentage of CFU recovered in four different fractions, sequentially eluted from the bottom of the column, with respect to the initial inoculum. (B) Dose-dependent inhibition of IHE3034 translocation through a mucin-gel matrix by anti-SslE antibodies. Serial dilutions (range 1:50–1:1350) of antibodies were used for inhibition. Antibodies against the unrelated ExPEC c1275 were used as a negative control at the dilution 1:50. Translocation was reported as the percentage of CFU recovered with respect to the initial inoculum for three sequentially eluted fractions. P values were determined using a two-tailed unpaired Student’s significance test.

doi:10.1371/journal.ppat.1004124.g003

dilutions principally affected bacterial translocation in the first two fractions. A higher dilution of 1:4050 did not show an inhibitory effect in any of the collected fractions (data not shown). The specificity of the inhibition was confirmed by the absence of an effect when using an antiserum against the unrelated ExPEC antigen c1275 [10], at the lowest dilution (Fig. 3B). On the other hand, since antibodies against a fragment of SslE, C-SslE_{IHE3034}, lacking the M60-like motif (Fig. S3A), were still capable of impairing IHE3034 translocation through the mucin layer (Fig. S3B), it is not possible to establish whether polyclonal antibodies have a direct or an indirect effect on SslE activity.

Antibodies against variant I SslE from IHE3034 inhibit \textit{E. coli} mucin translocation in strains expressing variant II SslE

As previously reported, SslE can be divided into two main variants [10]. Three hundred and eighteen \textit{E. coli} \textit{sslE} sequences were added to the 96 previously analyzed by Moriel et al. [10] (Table S1) and global amino acid sequence alignment revealed that sequence variability was present and distributed along the entire protein sequence. Overall, amino acid sequence identity ranged from 86–100%, with the HEXXHX(8,24)E core motif fully conserved in all sequences analysed. A total of 155 \textit{E. coli} unique protein sequences were identified and used to construct a phylogenetic tree (Fig. 4 and Table S2). The two main branches denoted the presence of two SslE clades (encoding for two variants: I and II). To understand whether antibodies raised against variant I can cross-inhibit the mucinolytic activity of other SslE subvariants, we selected a number of strains producing SslE variant II and belonging to different pathotypes. We tested the ability of an antisera against SslE from strain IHE3034 (SslE_{IHE3034}, belonging to variant I) to prevent the translocation of intestinal and extraintestinal strains expressing SslE belonging to variant II. In particular, we selected an EPEC strain (IC50), a SEPEC (septicemic-associated \textit{E. coli} belonging to ExPEC) strain (IN1S), an ETEC strain (GL53) and the EAHEC strain (LB226692) recently identified to be responsible for the 2011 German \textit{E. coli} outbreak. SslE_{IHE3034} antisemur inhibited the ability of all \textit{E. coli} pathotypes tested (expressing SslE variant II) to traverse the mucin-based matrix (Fig. 5).

SslE promoter is functional in a mouse model of intestinal colonization

The evidence that antibodies against SslE_{IHE3034} are functional and recognize different variants allows us to postulate that a vaccine containing this antigen may have the potential to protect against most pathogenic \textit{E. coli} species. In order to test the protective efficacy of SslE_{IHE3034} (variant I), we set up a mouse model of intestinal colonization using the ETEC GL53 strain. Mice were intragastrically infected with the bioluminescent GL53-Pem7-luxCDABE strain [27] and consistent bioluminescent signals were detected in the abdominal region until to 72 hours post-infection by the In Vivo Imaging System (IVIS) (Fig. 6A). As observed for other intestinal \textit{E. coli} pathotypes [28,29], bacterial infection mainly occurs in the caecum tract (Fig. 6B). This is consistent with data obtained by both CFU counts from infected intestinal ileum and caecum tracts (Fig. 6C) and confocal imaging of tissues (Fig. 6D and E). After setting up the GL53 intestinal colonization, we evaluated the functionality of the sslE promoter in vivo. 2D bioluminescent signal in the abdominal region could be observed when the luciferase expression was driven by the sslE promoter (Fig. 7A), compared to the positive control GL53-Pem7-luxCDABE. As expected, GL53 transformed with the luciferase promoterless plasmid gave no signal (Fig. 7A) [27]. In addition, 3D analysis confirmed that the signal was predominantly associated with the intestine (Fig. 7B). SslE transcription in GL53 colonizing bacteria was further evaluated by reverse transcriptase-polymerase chain reaction (RT-PCR), confirming that the sslE promoter is active in vivo (Fig. 7C).

Variant I SslE induces cross-protective immunity against variant II SslE expressing strains in intestinal colonization, UTI and sepsis mouse models

Cross-protective efficacy was evaluated by immunizing 30 mice intranasally with the recombinant variant I SslE and challenging
them with the ETEC strain GL53 (expressing variant II SslE).
Following immunizations with 30 μg of recombinant SslEIHE3034 at
days 1, 21 and 35, mice were infected by oral gavage with
5 x 10^7 CFU of GL53 at day 49. Intestinal caecum tracts were
collected at day 51, serial dilutions of the homogenized tissues were
plated and the CFU numbers were enumerated. A statistically
significant reduction (2.5 Log) in the mean value of GL53 bacterial
counts in the caecum was observed in mice immunized with the
SslEIHE3034 antigen versus those treated with saline (Fig. 8A). Anti-
SslE responses in protected mice consisted of antibodies belonging
to both IgG and IgA isotypes (Fig. S2C and D).

To further support the observation that SslEIHE3034 (variant I)
induces heterologous protection, we considered two alternative
models: a murine model of ascending UTI and a murine sepsis
model. In the UTI model, 30 mice were transurally inoculated
with either cholera toxin (CT) alone (as an adjuvant) or an
SslEIHE3034-CT mixture. Following three immunizations (days 0,
7, 14), animals were transurally challenged on day 21 with the
UPEC strain 536 (expressing SslE variant II) and protection was
assessed at 48 h post infection by determining the CFUs in the
urine, bladder, kidneys and spleen. SslEIHE3034 immunization led
to a significant reduction in median CFU/g (P = 0.0394) in the
kidneys and a more evident protection in the spleen with a 2.0 Log
reduction in median CFU/g (P = 0.0006) (Fig. 8B). In the sepsis
model, systemic E. coli infection was performed as recently
reported [10]. Active immunization with SslEIHE3034 followed by
challenge with the SEPEC strain IN1S (expressing SslE variant II)
provided significant protection from mortality (60% survival, P<
0.0001) (Fig. 8C).

Discussion

E. coli is a well-adapted human pathogen which uses the gut as a
preferential niche and, as for other intestinal microorganisms, it
bacterial translocation with or without anti-SslE antibodies was assessed in three sequentially collected fractions. For each strain, translocation of metabolic substrates vital to mucus-degrading bacteria [36–38]. In our study, the diminished capacity of the \( \text{sslE} \) mutant strain to translocate through a mucin-rich matrix in vitro suggests that SslE activity may facilitate bacterial penetration of the mucosal surface, including the inner mucus layer, to reach the underlying host epithelium. Although these data do not exclude that the catalytic function of such glycoproteins may also contribute to an increased fitness of \( E. \text{coli} \) in the outer mucus layer, the pathogenic strains that are armed with immune evasion virulence factors may use SslE as a spearhead to penetrate the sterile inner mucosal layer so as to intimately adhere to the epithelial cells of the host.

The core motif, HEXXXH, present in SslE is conserved in all families of the Clan of peptidase named MA (M for metallo) although it might also be present by chance in proteins with no peptidase activity [39,40]. Using the full putative metalloprotease domain of the ExPEC variant of SslE (residues: 1082–1382) to search the Pfam-A protein families database, we confirmed that the entire top 100 hits (E-value<8e-35) were M60-like domains (Pfam ID: PF13402). This domain is exclusively present in a family of the Clan of peptidase named MA (M for metallo) cleavage may account for the mechanisms of protection from \( \text{sslE} \) mediated protection against intestinal and extraintestinal strains was proposed as a universal vaccine candidate. The anti-mucin activity exerted by anti-SslE polyclonal antibodies in vitro, corroborated by a reduced colonization of caecum in mice immunized with recombinant SslE, further support the hypothesis that the impairment of mucin cleavage may account for the mechanisms of protection from \( E. \text{coli} \) infections in both the mucosal tissues of the gut and the urinary tract [48,49]. In addition, antibodies generated against SslE variant I showed cross-functional properties versus strains expressing variant II. Since polyclonal antibodies raised against full-length SslE are able to cross-inhibit antigen functional activity, we hypothesized that they may target conserved domains of SslE potentially involved in the metalloprotease activity. However, only a few strains were tested and further studies using a larger panel of clinically relevant strains would be required to confirm such an assumption.

In conclusion, the contribution of SslE to \( E. \text{coli} \) mucinolytic activity in vitro, and SslE mediated protection against intestinal and urinary tract colonization in vitro, indicate the importance of SslE as a novel colonization factor and a valid target for intervention strategies against disease caused by this important human pathogen.
Materials and Methods

Ethics statement

Animal studies regarding intestinal colonization and sepsis models were carried out in compliance with current Italian legislation on the care and use of animals in experimentation (Legislative Decree 116/92) and with the Novartis Animal Welfare Policy and Standards. Protocols were approved by the Italian Ministry of Health (authorization 236/2010-B) and by the local Novartis Vaccines and Diagnostics Animal Welfare Body (authorization AEC 201010). Animal studies for urinary tract infection experiments were conducted according to protocol #08999 approved by the University Committee on the Care and Use of Animals at the University of Michigan Medical School. The approved procedures are in compliance with University guidelines, State and Federal regulations, and the standards of the “Guide for the Care and Use of Laboratory Animals”.

Figure 6. ETEC strain GL53 is able to colonize the mouse intestine. (A) A group of 4 mice was infected with bioluminescent GL53 strain and monitored up to 7 days by IVIS System. The data displayed illustrate the results of a representative experiment. (B) Distribution of the bioluminescent GL53 strain in the intestinal tract of infected mice shows bacterial accumulation in the caecum. (C) Quantitative analysis of intestinal colonization by GL53. Briefly, ileum and caecum at 24 h, 48 h, 72 h and 7 days post infection were homogenized and plated for CFU counts. Symbols represent single mouse and the median is shown as bars for each time point. (D) Confocal staining of uninfected (left panel) and GL53 infected (right panel) ileum and caecum (left panel). Tissues were visualized with the red fluorescent Wheat Germ Agglutinin (Alexa Fluor 568-WGA, Life Technologies) and nuclei with the blue fluorescent DAPI. Bacteria were detected using polyclonal antibodies against GL53 and visualized by green Alexa Fluor 488-conjugated secondary antibody (Life Technologies). Bars: 10 μm.

doi:10.1371/journal.ppat.1004124.g006
Genomic DNA was isolated using the GenElute Bacterial Genomic DNA Kit (Sigma) according to the manufacturer’s instructions. ExPEC strain IHE3034 (serotype O18:K1:H7) was isolated in Finland in 1976 from a case of human neonatal meningitis [50]. Strains were cultured in Luria-Bertani (LB) broth at 37°C with agitation and aeration. E. coli DH5α-T1R (Invitrogen) was used for cloning purposes and E. coli BL21(DE3) (Invitrogen) was used for expression of His-tagged fusion proteins. The clones carrying a specific antibiotic resistance cassette were identified.

**Figure 7. The sslE promoter is functional in an intestinal model of colonization.** (A) 2D in vivo imaging at 24 hours of mice intragastrically infected with GL53-Pneg-luxCDABE (promoterless control vector), with the bioluminescent derivative GL53-PsslE-luxCDABE and with the GL53-Pem7-luxCDABE (positive control). (B) 3D image reconstruction showing sslE-promoter driven luciferase expression in E. coli localized in the intestinal tract. (C) RT-PCR of RNA purified from: in vitro lab-grown GL53 bacteria (lane 2, positive control); caecum tract of uninfected mice (lane 3, negative control); GL53 bacteria recovered from infected mice (lane 4); GL53 bacteria recovered from infected mice without the RT step (lane 5). 1 Kb Plus DNA Ladder (Life Technologies) is shown in lane 1. doi:10.1371/journal.ppat.1004124.g007

**Bacterial strains and culture conditions**

Genomic DNA was isolated using the GenElute Bacterial Genomic DNA Kit (Sigma) according to the manufacturer’s instructions. ExPEC strain IHE3034 (serotype O18:K1:H7) was isolated in Finland in 1976 from a case of human neonatal meningitis [50]. Strains were cultured in Luria-Bertani (LB) broth at 37°C with agitation and aeration. E. coli DH5α-T1R (Invitrogen) was used for cloning purposes and E. coli BL21(DE3) (Invitrogen) was used for expression of His-tagged fusion proteins. The clones carrying a specific antibiotic resistance cassette were identified.

**Figure 8. SslEIHE3034 induces cross-protection in intestinal colonization, UTI and sepsis models.** (A) Thirty CD1 mice were intranasally immunized with 30 μg of SslEIHE3034 at days 1, 21 and 35. Saline was used in the negative control groups. Challenge was done by oral gavage with 5 × 10⁷ CFU of strain GL53 at day 49. Serial dilutions of the homogenized intestinal caecum tract were plated and the CFU number was enumerated. Statistical significance of protection was obtained using the Mann Whitney test. (B) SslEIHE3034 prevents the spread of the UPEC strain 536 into the kidneys and spleen in an ascending model of urinary tract infection. Thirty mice were immunized intranasally with 10 μg cholera toxin (CT) alone or with 100 μg of SslEIHE3034 at a 1:10 ratio of antigen:CT (day 1). After two boosts of 25 μg antigen (10:1 ratio of antigen to CT) or CT alone (day 7 and 14), mice were transurethrally challenged with 10⁷ CFU of strain 536 at day 21. After 48 h, bladder, kidneys and spleen were harvested and homogenized. Bacteria in urine and in the tissue homogenates were enumerated by plating serial dilutions. Symbols represent CFU/g tissue or CFU/ml urine of individual mice, and bars indicate median values. P values were determined using the nonparametric Mann-Whitney significance test. (C) SslEIHE3034 protects against the SEPEC strain IN1S in a sepsis mouse model. CD1 out-bred mice were immunized by subcutaneous injections at day 1, 21, and 35 with 20 μg of recombinant SslEIHE3034 formulated with alum or alum alone. Immunized animals were challenged at day 49 with a sublethal dose of heterologous strain IN1S and survival was monitored for up to 4 days. The results are indicated as percentage of survival out of a total number of 40 mice. P values were determined using the nonparametric Mann-Whitney significance test. doi:10.1371/journal.ppat.1004124.g008
grown in the presence of kanamycin (50 µg/ml) or ampicillin (100 µg/ml).

Construction of sslE deletion mutant and complemented strains

The isogenic sslE knockout mutant strain was constructed by replacement of the entire gene by an antibiotic resistance cassette. The upstream and the downstream regions of the sslE gene were amplified by PCR with the primers 1–2 and 3–4 (Table S3), using IHE3034 chromosomal DNA as template, and cloned into the pBluescriptKS (Stratagene). The kanamycin resistance cassette was inserted between the two flanking regions in the plasmid. The resulting plasmid was used to electroporate the target strain. Single transformants were confirmed by PCR and Western blotting. Complemented strains were obtained by transformation of the sslE mutant with sslE_WT and sslE_mut recombinant plasmids, carrying the sslE wild-type gene or the gene mutated in the putative metallopeptidase motif. For amplification of the sslE gene, E. coli IHE3034 genomic DNA was used with the primers 5 and 6 (Table S3). The triple mutation (mut) (H1274Y+E1275V+H1278Y) was obtained by two overlapping PCRs performed with primers 7, 8 and 9 (Table S3). Finally, the sslE_WT and sslE_mut constructs were generated carrying the sslE predicted promoter region upstream of the sslE gene. The two clones harboring these plasmids were produced by a PIPE method [51] that is based on the transformation of HK100 E. coli cells with a mix of a vector/insert PCR. The vector PCR was performed using the sslE_WT and sslE_mut templates with primers 10 and 11 (Table S3), while the insert PCR was obtained with E. coli IHE3034 genomic DNA template and primers 12 and 13 (Table S3).

Confocal staining of pathogenic E. coli bacterial cells

E. coli strains were grown to exponential phase in LB medium and fixed in PFA 1% for 20 min on a poly-L-lysine-coated slide (Thermo scientific). After a blocking step in PBS+1% BSA, slides were incubated with anti-Sse IgG rabbit serum and then with a donkey anti-rabbit IgG Rhodamine RedX-conjugated antibody (Jackson Immuno-Research Laboratories). IHE3034 bacteria were localized using mouse polyclonal antibodies raised against whole cell IHE3034, and the green fluorescent Alexa Fluor488 goat anti-mouse IgG. The samples were mounted using the Pro-Long Gold antifade reagent containing the blue-fluorescent nuclear counterstain DAPI (Invitrogen). Images were acquired using a 100 x oil objective (1.4 n.a.) mounted on a Zeiss LSM710 confocal microscope. In the pictures the signal from SslE was pseudocoloured in green, while the signals from bacteria are shown in red. Z-stacks of images were deconvoluted using Velocity Software (Improvision).

In vitro mucinase activity assays

1. Amido black assay. Pathogenic E. coli from mid-log culture phase were incubated on LB-agar plates containing 0.5% bovine submaxillary mucin (SIGMA), stained with 0.1% (wt/vol) amido black in 3.5 M acetic acid for 30 min and destained with 1.2 M acetic acid.

2. Detection of mucinase activity by IVIS. IHE3034 wild-type, IHE3034sslE knockout mutant, IHE3034sslEZ::sslE_WT and IHE3034sslEZ::sslE_mut were transformed by electroporation with the pGEN-luxCDABE plasmid (Amp+) expressing luciferase (lux) strains. Plasmid stability was assessed in all strains by CFU counting on LB and LB-Amp100 plates. A soft gel mucin-based matrix was allowed to polymerize in round 5-ml plates. 5 x 10^7 CFU of mid-log E. coli plux strains were loaded into wells cut in the middle of the plate and incubated statically at 37°C. Starting inocula were plated to determine the loaded CFU. Pictures were acquired by IVIS 100 time 0 and at 24 h.

3. Mucin gel degradation assay. 10^8 CFU of pathogenic E. coli strains from mid-log culture phase were layered on top of 1 ml soft gel-matrix polymerized together with 10% submaxillary gland mucin (SIGMA) in 1 ml syringes and incubated statically for 3 h at 37°C in a vertical position (starting inocula were determined as CFU at time 0). 100 µl fractions were sequentially collected from the bottom of the syringe, diluted and plated. The counts were calculated as % of recovered bacteria in each fraction, sequentially eluted from the column, with respect to the starting inoculum. Data presented are the mean of three independent experiments performed in duplicate. Antibody inhibition of mucin degradation was performed by adding different sera dilutions to the soft gel mucin-based matrix before the polymerization.

PCR amplification and sequence variability analysis of sslE gene

Amplification and sequencing of the sslE gene was performed as previously described [10]. Assembly, alignment and comparison of the Sse deduced amino acid sequence was performed with GENEIOUS V6 software (Biomatters. Available from http://www.geneious.com/). In addition to the 96 sslE sequences used by Moriel et al. [10], 318 E. coli sslE sequences were included. The final dataset comprised 414 isolates which comprised EXPEC, InPec and faecal isolates. Further, sequences relative to unknown E. coli pathotypes were extracted from the NCBI database (Table S1). 155 unique Sse protein sequences were selected using GENEIOUS V6 software. The phylogenetic tree was inferred from the alignments by the neighbor-joining distance-based method implemented on MEGA4 [52].

Cloning, expression and purification of Sse recombinant protein

The sslE gene was amplified by PCR from the IHE3034 genomic DNA template, cloned into the pET21b vector (Novagen) and transformed into DH5α-T1R chemically competent cells for propagation. BL21(DE3) chemically competent cells were used for His-tagged protein expression. The protein was purified by nickel chelating affinity chromatography using a HisTrap HP column (GE Healthcare) followed by anionic exchange chromatography. The purified protein was finally dialyzed in phosphate-buffered saline (PBS) and stored at -20°C.

In vivo monitoring of sslE promoter activity

The Psse-luxCDABE plasmid was obtained by replacing the constitutive Prom7 promoter of the pGEN-luxCDABE with the sslE putative promoter region. To obtain the predicted sslE promoter region, a 484-bp fragment was amplified from IHE3034 genomic DNA by PCR using the primers 14 and 15 (Table S3). Chemically competent DH5α cells (Life Technologies) were used for transformation and ampicillin (Amp100) was used as a marker of selection. The resulting Psse-luxCDABE plasmid was confirmed by sequence analysis and used to transform the ETEC strain GL53 by electroporation, resulting in the GL53-Psse-luxCDABE strain. Ten-week old C57BI female mice (Charles River) were infected intragastrically with 5 x 10^10 CFU of either the bioluminescent ETEC GL53-Psse-luxCDABE strain or GL53-Pneg-luxCDABE.
(promoterless control vector). Imaging of mice anesthetized with isoflurane (4% initially, 1.5% during image acquisition) was performed with an IVIS Spectrum CT Imaging System (Perkin Elmer). Detection of 2D bioluminescent signals was carried out without filters (open), binning 8 and times of acquisition from 1 s to 1 min. 3D images were acquired with six filters (500, 520, 560, 580, 600 and 620 nm), using the same binning and acquisition times and reconstructed by the Living Image software (version 4.3.1).

Reverse transcriptase-PCR

The GL53 infected caecum was homogenized using gentle-MACS Dissociator (MiltenyiBiotec) in 10 ml PBS. After filtration and centrifugation, the pellet was incubated for 5 minutes at room temperature in 3 ml of RNA protect Bacteria Reagent (Qiagen). After cell lysis, total RNA was purified using the RNeasy Mini kit (Qiagen) and an additional DNase treatment was done using the TURBO DNA-free kit (Applied Biosystem), according to the manufacturer’s protocols. Purity of RNA was assessed by electrophoresis on agarose gels. Reverse transcription and amplification of an sslE fragment with the primers 16 and 17 (Table S3) from RNA were performed using the SuperScript III One-Step RT-PCR System with Platinum Taq DNA Polymerase kit (Invitrogen).

Mouse model of intestinal colonization

Five-week old CD1 mice were intranasally immunized with 30 μg of SslE antigen at days 1, 21 and 35. Saline was used as a negative control. Fourteen days after the last immunization mice were streptomycin-treated (for 2 days) to eradicate the resident flora and then they were infected by oral gavage with 5 x 10^5 CFU/400 μl of strain GL53/Amp'. Forty-eight hours after challenge, mice were euthanized and the intestinal caecum tract was recovered and homogenized. Serial dilutions of the suspension were plated on LB/Amp100 plates and the CFU were enumerated. Statistical significance of protection was determined using the Mann Whitney test.

Urinary tract infection model

Female CBA/J mice, 6 to 8 weeks old, were transurethrally inoculated as previously described [53]. Purified antigen was mixed with cholera toxin (CT) (Sigma) at a ratio of 10:1. The vaccine was administered intranasally in a total volume of 20 μl/animal (10 μl/nostril). Animals received a primary dose on day 0 of 100 μg antigen (containing 10 μg CT) or 10 μg CT alone. Two boosts of 25 μg antigen (mixed with 2.5 μg CT) or 2.5 μg CT alone were given on days 7 and 14, and mice were challenged on day 21. E. coli 536 suspensions in phosphate-buffered saline (PBS) (50 μl/mouse) were delivered transurethrally using a sterile 0.28-mm-inner-diameter polystyrene catheter connected to an infusion pump (Harvard Apparatus), with a total inoculum of 10^9 CFU/mouse. For determination of CFU, organs were aseptically removed from euthanized animals at 48 h post inoculation and homogenized in PBS with a GLH homogenizer (Omini International). Bacteria in tissue homogenates were enumerated by being plated on LB agar containing 0.5 g/liter NaCl using an Autoplate 4000 spiral plater (Spiral Biotech), and CFU were determined using a QCount automated plate counter (Spiral Biotech). Blood was collected as necessary from anesthetized mice by an infraorbital bleed using 1.1- to 1.2-mm Micro-Hematocrit capillary tubes (Fisher), and serum was separated using Microtainer serum separator tubes (Becton Dickinson). The animals were ≤15 weeks old at the conclusion of all experiments.

Sepsis mouse model

CD1 outbred mice were immunized by subcutaneous injections at day 1, 21, and 35 with 20 μg of recombinant SslE_IHE3034 formulated with alum or alum alone. Immunized animals were challenged at day 49 with a sublethal dose of a heterologous strain and survival was monitored for up to 4 days. The results are indicated as the percentage of survival from a total number of 40 mice. P values were determined using the nonparametric Mann-Whitney significance test.

Statistical analysis

Mean values, standard deviation values, and the P values associated to two-tailed unpaired Student’s t test were calculated using the Microsoft Excel application. A P value<0.05 was considered statistically significant.

Supporting Information

Figure S1 Polysialic acid capsule interferes with SslE detection on E. coli K1 IHE3034. (A) Flow cytometry detection of K1 capsule on wild-type strain IHE3034 (left panel) and acapsulated IHE3034Δkps strains (right panel) by anti-capsule monoclonal antibody SEAM12 (blue lanes). Serum from animals immunized with PBS was negative control (red). (B) SslE surface detection on wild-type IHE3034 (left panel) and its derivative lacking the capsule IHE3034Δkps (right panel) by anti-SslE immune sera (blue lines) compared to the PBS negative control (red). (C) Titration of binding by an anti-SsslE rabbit serum on both IHE3034Δkps acapsulated (red) and IHE3034ΔkpsΔsle (blue) strains. (D) Confocal microscopy images of SslE surface localization on IHE3034Δkps and (E) IHE3034ΔkpsΔsleI. Bacteria were visualized with both DAPI (DNA marker, blue) and FM4-64 Dye (membrane marker, red). SslE was detected using the anti-SsslE rabbit serum and a fluorescent secondary antibody (green). Merged images are also displayed. Bars: 2 μm. (TIF)

Figure S2 IgG and IgA antibody response following SsslE immunization. Immunoglobulin levels were quantified by ELISA. Briefly, 100 ng/well of purified SsslE was incubated with serial dilution of sera for 2 h at 37°C. Following detection with Alkaline Phosphatase [AP] conjugated secondary antibody, OD405 values were plotted in the titration curves. (A) IgG and (B) IgA response derived from serum of immunized rabbit (circles) compared to the negative control (square). (C) IgG and (D) IgA response in pool of sera derived from immunized mice (circles) compared to the negative control (square). Each point represents the means ± standard deviations. (TIF)

Figure S3 Polyclonal antibodies against the truncated C-SsslE impair E. coli translocation through a mucin matrix. (A) Schematic representation of the C-SsslE truncated form lacking the Zn-metalloprotease domain compared to the full-length SsslE protein. (B) Inhibition of wild-type IHE3034 translocation through a mucin-gel matrix by anti-C-SsslE antibodies compared to negative controls. (TIF)

Figure S4 Comparison of the SsslE core motif with other M60-like members. The figure reports a multiple sequence alignment of the SsslE core motif of the zinc metallopeptidase M60-like domain versus the best hits that were found when searching the Pfam-A database. The extended core motif is shown by a dotted square and the conserved residues of the core motif are indicated with an
asterisk. The species names are followed by the UniProt accession codes in brackets.

**(TH)**

**Table S1** List of strains used for global SslE amino acid sequence alignment.

**(PDF)**

**Table S2** List of SslE unique sequences.

**(PDF)**

**Table S3** List of primers used in the study.

**(PDF)**

**Methods S1** Detailed description of the experimental procedures relative to the data reported in Fig. 6, Fig. S1 and Fig. S2.

**(DOCX)**

**Text S1** Polysialic acid capsule interferes with SslE detection on *E. coli* K1 IHE3034. By comparing the SslE-specific signal between IHE3034 WT and the IHE3034Akp5 deletion mutant by FACS and confocal imaging analysis, we demonstrated that the K1 capsule clearly interferes with the anti-SslE antibody accessibility and recognition of the protein on the bacterial surface.

**(DOCX)**

**Text S2** IgG and IgA antibody response following SslE immunization. We observed that subcutaneous immunization of rabbit with recombinant SslE generated a high response in terms of IgG, while IgA values were low.

**(DOCX)**

**References**

rhagic *E. coli* in mice using bioluminescent *in vivo* imaging. Gut Microbes 2: 34–41.


